VYNE Therapeutics Inc. (VYNE)
 NASDAQ: VYNE · Real-Time Price · USD
 0.3664
 +0.0198 (5.71%)
  At close: Oct 30, 2025, 4:00 PM EDT
0.3730
 +0.0066 (1.80%)
  Pre-market: Oct 31, 2025, 4:32 AM EDT
VYNE Therapeutics Employees
VYNE Therapeutics had 13 employees as of December 31, 2024. The number of employees increased by 3 or 30.00% compared to the previous year.
Employees 
 13
Change (1Y) 
 3
Growth (1Y) 
 30.00%
Revenue / Employee 
 $36,615
Profits / Employee 
 -$2,965,000
Market Cap 
9.33M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 13 | 3 | 30.00% | 
| Dec 31, 2023 | 10 | -2 | -16.67% | 
| Dec 31, 2022 | 12 | -16 | -57.14% | 
| Dec 31, 2021 | 28 | -78 | -73.58% | 
| Dec 31, 2020 | 106 | 66 | 165.00% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
VYNE News
- 2 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 6 months ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 6 months ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga
- 6 months ago - VYNE Therapeutics Provides Update on VYN202 Program - GlobeNewsWire
- 8 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 8 months ago - VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire